tokens: This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ), toxicities , and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ). PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis-RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .